about
Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Targeting of erbB3 receptor to overcome resistance in cancer treatmentMesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent.Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of SurvivinTherapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells.Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells.The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cellsThe anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.Glucose promotes breast cancer aggression and reduces metformin efficacy.Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.Role of erbB3 receptors in cancer therapeutic resistance.Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells.Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells."Sister" miRNAs in cancers.Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer CellsDevelopment of Effective Therapeutics Targeting HER3 for Cancer TreatmentThe monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathwayDownregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells
P50
Q24813382-3E3CA2E8-D5DD-4F3D-B473-212379AD38A8Q24813543-2BB9761C-F8D5-4E44-9DE4-C3AC157DA93BQ26864668-3D28FB00-96F8-4836-951A-18202F567BD3Q27317754-655996C8-FA5B-4B3D-AA80-1BC87B3DF84BQ28283239-2ADFA4AC-09C1-48A7-9A95-45BEA5579398Q33934617-B5669C66-F52F-45AF-A7D4-7850F35B20ADQ35835794-A6980AAE-9E46-437C-9ACE-142E40ECE375Q35914683-BD0EF8BF-D4FB-4C1A-892A-99090D14EE38Q36623480-F18CCF4A-C1EA-4A47-997F-B66EFFC958A5Q36670785-7D75DCAF-535B-4AEA-B6E7-23CDA30868B2Q36771985-ADE002A2-7269-49C7-B493-527CEC87684EQ37312071-576B9BB9-3F33-4C07-8827-6CD28F99DE79Q37525828-0B032609-8015-42B1-B3B0-B24B730F7F34Q37690272-E21AD74A-4FE2-49BD-AF82-73E4D294A259Q38180692-ECF01C2C-F93B-4753-8649-434775EEF454Q38790790-A3BF758D-E4C4-41DF-AE60-B0083F0E4067Q39485621-BA7A4A9B-825B-4998-BF7F-03A98127D29FQ39706886-48A7B726-AF35-4053-A890-4A9D18DB9435Q39782846-948FB60F-8648-4BE3-A6DC-2AB0C4514F17Q40246736-FE98D7BC-3093-4371-8CCD-507F9811A120Q41708988-55E456AA-039C-4D65-B1F7-1000AF51B8A4Q42731994-B2DAEFF7-3A13-47E7-8265-74EF3AE68F4CQ43576697-8749DB2C-F8E2-4416-935C-870B659D740DQ43583339-5E7ADF01-1E03-4EAE-AB8C-CACC25DE0782Q44450066-6575E068-D4E9-4047-B227-7AA41239881DQ45058304-DC122A15-7217-4FE0-B13A-C8B91B9BCDB1Q45259942-8CC1DA3B-CE83-4F18-8630-3823BA296670Q58796351-5D5CC2FC-38D4-4717-9E83-DF959CF0BD19Q64073566-A85C1CE7-5155-483B-A844-2DCC80C2F6ECQ74141677-56239D96-6A73-47A8-976B-37663D7FEF04Q79696543-8E939E86-2CA4-4AA8-9057-C0DAC2B129D3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bolin Liu
@ast
Bolin Liu
@en
Bolin Liu
@es
Bolin Liu
@nl
Bolin Liu
@sl
type
label
Bolin Liu
@ast
Bolin Liu
@en
Bolin Liu
@es
Bolin Liu
@nl
Bolin Liu
@sl
prefLabel
Bolin Liu
@ast
Bolin Liu
@en
Bolin Liu
@es
Bolin Liu
@nl
Bolin Liu
@sl
P106
P1153
7408692467
P31
P496
0000-0003-0150-8650